MAPK1 and RASopathy: Functional studies used to identify the pathogenicity of a RASopathy gene variant have relied on biochemical analysis or animal modeling to demonstrate ERK activation/dysregulation, which is the final MAPK effector of the RAS/MAPK pathway, with phosphorylated ERK1/2 having a plethora of nuclear and cytosolic targets.